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ABSTRACT
Adolescent cannabis use has grown because of increased availability and higher
societal acceptance. This increase in cannabis use is problematic as
adolescents who experiment with cannabis are more likely to abuse cannabis
and experiment with other illicit drugs such as cocaine. The reason for the
greater susceptibility to drugs use is unclear and may be the result of altered
drug sensitivity after cannabis exposure. Thus, the present investigation used
the behavioral sensitization paradigm to examine the behavioral response of
early adolescent rats to the cannabinoid agonist CP 55,940 (CP) or cocaine after
repeated cannabinoid administration. It was hypothesized that: (1) CP would
cause a sensitized response in both male and female adolescent rats, (2) female
rats would have a greater behavioral response than male rats, (3) pretreatment
with CP would induce cross-sensitization to cocaine, (4) pretreatment with
cocaine would cause behavioral sensitization and conditioned activity in male
and female adolescent rats. In the first experiment, 137 male and female
Sprague-Dawley rats were given CP (4, 13.2, or 40 µg/kg, IP) or vehicle (50%
DMSO/H2O) once daily for 5 consecutive days on postnatal day (PD) 30- PD 34.
Distance traveled and stereotyped movement was assessed for 1 h after each
drug injection. After a 48 h abstinence period (i.e., on PD 36), rats were given CP
(4 or 13.2 µg/kg, IP) and distance traveled and stereotyped movement was
monitored for 2 h. In the second experiment, 146 male and female rats were
tested with the same protocol as in Experiment 1 except that rats were given CP
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(13.2 or 4 µg/kg), cocaine (20 mg/kg), or vehicle (saline or 50% DMSO/H2O) for
five days and then tested with saline or cocaine (10 mg/kg) after 48 h. In the first
experiment, no dose of CP altered distance traveled scores or stereotyped
movement over the five pre-exposure days nor did CP cause behavioral
sensitization on the test day. In the second experiment, pretreatment with
cocaine led to enhanced distance traveled scores and stereotyped movement
when challenged with cocaine (behavioral sensitization) or saline (conditioned
activity) on test day. In contrast, CP-pretreated rats did not show greater activity
when injected with cocaine or saline on test day. These data show that
cannabinoids do not act like psychostimulant drugs, since CP did not cause the
same changes in drug sensitivity as cocaine. The cocaine sensitization observed
in adolescent rats indicates that this age group is particularly vulnerable to the
rewarding effects of cocaine, and suggests that early cocaine exposure can
augment drug seeking behavior. The failure to detect cannabinoid-induced
sensitization, conditioned activity, or cocaine cross-sensitization during
adolescence suggests that CP, when given at a consistent dose, does not
increase the addictive properties of cannabinoids or cocaine. The results also
indicate that cannabinoid use does not alter drug responsivity or lead to greater
drug seeking and abuse in the adolescent population.
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CHAPTER ONE
INTRODUCTION

Cannabis
Cannabis has been called by several names including hemp, hashish,
ganja, and marijuana (Russo, 2007). The cannabis plant has been used for
clothing, paper, rope, and as a medicine throughout many time periods in various
cultures. Emperor Shen Neug of China in 2,000 B.C. was the first to record
cannabis use, or ‘ma’ as a textile and for soil fertilization (Zuardi, 2006). Hemp
rope was also used by the Vikings for both coarse textiles and fine household
textiles (Skoglund, Nockert & Holst, 2013). This plant has also been used in
religious and spiritual rituals for enlightenment and communication with spirits
(Bapat, 2015; Russo, 2007; Touw, 1981; Zuardi, 2006). The Materia Medica
Sutra (Pen ts’ao Ching) first documented the psychotropic properties of cannabis
sativa L. (Huo ma ren) and refers to the “fruit of the cannabis” which if taken
would cause the user to have visions of spirits and devils (Zuardi, 2006).
Throughout history, various cultures and religions have noted that cannabis may
have useful properties (Aldrich, 1997).
The Chinese were also the first to document the medical uses of cannabis
for pain reduction, female reproductive health, and constipation relief (Touw,
1981; Zuardi, 2006). Common medical uses for cannabis that have been
reported by cultures throughout Asia and the Middle East include analgesia,
appetite stimulation, diarrhea relief, and mental relaxation (Bapat, 2015; Russo,
1

2007; Touw, 1981; Zuardi, 2006). However, cannabis also produces euphoric
and psychoactive effects that have influenced cultures to outlaw its use. For
example, the Chinese called the resinous seeds (Ma Fen) poisonous and made it
illegal to consume them (Li, 1978; Russo, 2007; Touw, 1981; Zuardi, 2006).
Furthermore, India prohibited cannabis resin (haras) despite cannabis (bhang)
being considered one of the five sacred plants of India (Bapat, 2015; Russo,
2007; Touw, 1981; Zuardi, 2006).
The United States also has a long history with cannabis. In 1916 botanists
Lyster H. Dewey and Jason L. Merrill of the Department of Agriculture reported
that hemp would make a more efficient and environmentally safer paper
compound compared to wood (Dewey & Merrill, 1916, pg. 25). However, the
prohibition of marijuana had already begun in California in 1915. In 1937, the
United States Congress passed the Marijuana Tax Act which made anyone
selling marijuana pay an occupational tax and register with the Internal Revenue
Service (McKenna, 2014; Musto, 1972). This act passed with the help of
negative propaganda like the film “Reefer Madness” (Stringer & Maggard, 2016).
Interestingly, Harry Anslinger and the Federal Bureau of Narcotics passed the
Marijuana Tax act essentially outlawing cannabis in 1937, the same year Dr.
William C. Woodward of The American Medical Association proposed the study
of cannabis for medical use (McKenna, 2014; Newton, 2014).
The Controlled Substance Act was then passed in 1970 and banned the
medical and recreational use of marijuana by placing it on the Schedule I drug
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list, the most restrictive drug schedule. Drugs that are on this schedule are
defined as drugs with no currently accepted medical use and a high potential for
abuse. Nevertheless, in 1992, the first pharmaceutical based cannabis
compound, dronabinol, became legal for medical use specifically for AIDSwasting syndrome (Werner, 2001). In 1996, California became the first of 25
states to decriminalize medical marijuana for persons in California suffering from
cancer, glaucoma, migraines, seizures, severe nausea, muscle spasms, and
chronic pain. In 2012, Colorado and Washington decriminalized cannabis
recreationally for people over the age of 21, and Alaska and Oregon followed suit
in 2014. Most recently, California has passed laws for recreational use beginning
in 2017. Despite these changes in state law, the federal government still
considers cannabis an illicit substance and it remains listed as a Schedule I drug.
Cannabis Plant
The cannabis plant grows indigenously in many regions, in Asia and the
Middle East. The two main species of the cannabis plant are indica and sativa.
In addition, a number of genetic hybrids have been created through cross
breeding of indica and sativa plants (Russo, 2007). The indica strain of the plant
grows short and stocky with dark leaves while the sativa strain grows tall and thin
with light leaves (Russo, 2007). Different types of sativa and indica strains have
been shown to produce differing effects and are now being classified by their
genetic makeup and reported medical benefits (Janatová et al., 2018). Cannabis
indica has been reported to have pain relieving effects on the body, produce
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sedation, and help with nausea and lack of appetite (Pearce, Mitsouras & Irizarry,
2014). The sativa strains, on the other hand, are self-reported to cause euphoric
and psychedelic effects and are considered energizing and stimulating (Pearce
et al., 2014).
There are three main preparations of the cannabis plant including the
cannabis resin (hash), the seeded plant that contains stems, flowers, and leaves,
and the unfertilized female flowers which are most commonly used to produce
psychoactive effects (Russo, 2007). The cannabis flowers contain numerous
active chemical compounds known as cannabinoids, which are responsible for
the altered state that is experienced by someone who uses the cannabis plant.
The two main cannabinoids of this plant, (−)-trans-Δ9-tetrahydrocannabinol
(THC) and cannabidiol (CBD), are believed to mediate most cannabis-induced
effects (Russo, 2007).
When used acutely, cannabis can cause red eyes, sleepiness, decreased
motor coordination, and slow respiratory rate (Grotenhermen, 2004). The
psychological effects observed with acute cannabis use include dysphoria,
alterations to attention, concentration, and learning, and somatic and visual
sensations (Grotenhermen, 2004). Although the acute effects are well
understood, the persistent long-term effects of cannabis use are variable and
depend on age of onset and duration of use. Overall, decreases in verbal
fluency, visual attention, and executive functioning have been associated with
cannabis use that is initiated before the age of 15 (Fontes et al., 2011).
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Conversely, onset of cannabis use after the age of 15 does not produce the
same long-term consequences. Cannabis withdrawal is common in adults but
people do not commonly seek treatment for these symptoms. Cannabis
withdrawal can include irritability, difficulty sleeping, restlessness, and changes in
mood such as depression and nervousness (Gorelick et al., 2012; Verweij et al.,
2013). In sum, the cannabis plant contains cannabinoids that can acutely
produce desirable effects but can also have long-term consequence, especially if
the onset of use begins at an early age.
Challenges of Cannabis Legalization
Even though cannabis is still illegal according to the United States federal
government, the decriminalization of cannabis by several states has led to the
development of numerous marketable products with varying levels of potencies
(ElSohly et al., 2016). Today the cannabis flowers sold in recreational cannabis
shops can contain THC levels averaging around 20% compared to an average of
about 4% in 1995 (Elsohly et al., 2016). This increase in potency means that
current THC effects are no longer comparable to those observed in earlier
research and, thus, the effects of this level of potency are not well understood
(Vergara et al., 2017). Furthermore, concentrated waxes that can contain up to
100% THC have been popularized recently (Loflin & Earlywine, 2014). These
concentrated waxes known as “dabs” are self-reported to cause increased
tolerance and withdrawal to THC (Loflin & Earlywine, 2014). Cannabis is also
processed into oils and butters that are turned into candies, drinks, condiments,
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and other daily food items, which has led to unforeseen issues. For example,
with no federal regulations to control access to these poorly labeled cannabis
products there has been an increase in accidental exposure in young children
(Davis et al., 2016; Wang et al., 2014).
Cannabis has become the most commonly used illicit substance in the
United States (Johnston et al., 2018). The changes in the legalization of
cannabis, especially in states supporting cannabis, has led to an increase in
reports of cannabis dependence and abuse (Cerdá, Wall, Keyes, Galea & Hasin,
2012). Cannabis use disorder is characterized by the following criteria; the use of
cannabis for over 1 year, uncontrolled craving and consumption that are related
to the user having difficulty controlling use, difficulty quitting use, or significantly
impairing daily life functioning (American Psychological Association, 2013).
Although cannabis use disorder is seen at lower rates than other disorders
involving illicit substances, its prevalence is increasing primarily among the
young adult population (Haberstick et al., 2014; Peer et al., 2013). Late
adolescence and early adulthood populations are at the highest risk of cannabis
use disorder, with the most susceptible age of onset ranging from 14-24 years of
age (Farmer et al., 2015). In fact, patients with a lifetime diagnosis of cannabis
use disorder report that their first episode of cannabis dependence was under the
age of 18 (Farmer et al., 2015) As a result, this young population is vulnerable to
cannabis use disorder, thus, making the consequences of adolescent cannabis
use an issue of public health concern (Haberstick et al., 2014).

6

CHAPTER TWO
THE ENDOCANNABINOID SYSTEM:
RECEPTORS
After the primary psychoactive component of cannabis, THC, was
identified, it was quickly discovered that this compound works by binding to
distinct receptors in the central and peripheral nervous systems. These
receptors were labelled cannabinoid receptors, which includes the cannabinoid
one (CB1) and cannabinoid two (CB2) receptors (For review; see Howlett et al.,
2002). Endogenous ligands were eventually found to bind to these receptors, the
two endogenous cannabinoid ligands are anandamide and 2arachidonoylglycerol (2-AG; Bisogno et al., 1999; Felder et al., 1996). Together,
the receptors and the endogenous ligands are known to be important
neuromodulators of neuronal activity. In particular, the endocannabinoid system
is important for the modulation of pain, feeding, neuroprotection, and reward (For
review; see Howlett et al., 2002).

Cannabinoid Receptors
CB receptors have been characterized across human, porcine, primate,
and rodent brains (For review; see Howlett et al., 2002). Until recently, CB1
receptors were thought to only exist in the central nervous system whereas CB2
receptors were confined to the peripheral nervous system. Now it is known that
both receptors are distributed throughout the brain and body (Gong et al., 2006).
CB receptors are composed of seven hydrophobic segments that consist of N-
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terminal extracellular and C-terminal intracellular domains (For reviews; see
Howlett et al., 2002; Pertwee, 1997; Svíženská, Dubový & Šulcová, 2008). The
CB1 receptor has been extensively studied but the CB2 receptor is not as well
understood. Additionally, there has been discussion of a third CB receptor, the
vanilloid receptor (TRPV1 or VR1), with similar neurological functions and
expression as the endocannabinoid system (Cristino et al., 2006).
Adult Distribution and Density
CB1 receptors are expressed in adult rats on the terminal axonal fibers of
neurons, specifically on presynaptic terminals (Howlett et al., 2002). CB1
receptors are located throughout the limbic system, are involved in the formation
of memories and play an important role in behavior and cognition (Egertová &
Elphick, 2000; Herkenham et al., 1991, Mailleux & Vanderhaeghen, 1992;
Rajmohan & Mohandas, 2007). Overall, the hippocampal formation has more
dense binding than other areas of the brain (Herkenham et al., 1991; Mailleux &
Vanderhaeghen, 1992). The densest binding is found in the molecular layer of
the dentate gyrus and the CA1 and CA3 regions of Ammons horn (Egertová &
Elphick, 2000; Herkenham et al., 1991, Mailleux & Vanderhaeghen, 1992). In
contrast, binding in the granule cell layer of the dentate gyrus is scarce
(Herkenham et al., 1991, Mailleux & Vanderhaeghen, 1992). Similarly, the
septum and amygdala exhibit sparse binding (Herkenham et al., 1991, Mailleux &
Vanderhaeghen, 1992).
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In adult rats, the second densest site of CB1 receptors is the basal
ganglia, which controls movement, coordination, and procedural learning
(Herkenham et al., 1991, Mailleux & Vanderhaeghen, 1992). Specifically, within
the basal ganglia the highest densities of CB1 receptors are found in the globus
pallidus, entopeduncular nucleus, and substantia nigra pars reticulata (Egertová
& Elphick, 2000; Herkenham et al., 1991, Mailleux & Vanderhaeghen, 1992;
Matsuda, Bonner & Lolait, 1993; Tsou, Brown, Sanudo-Pena, Mackie & Walker,
1998). These areas of the basal ganglia show a gradient of binding intensity that
increases from the medial to the lateral regions (Egertová & Elphick, 2000). In
the striatum, the dorsolateral region has denser binding than the ventromedial
area, while the nucleus accumbens has moderate to low densities of CB1
receptors (Herkenham et al., 1991; Mailleux & Vanderhaeghen, 1992). The
basal ganglia also has CB1 receptors in white matter tracts. Specifically, the
striatonigral descending pathway contains detectable CB receptors (Herkenham
et al., 1991).
The density of CB1 receptors in the cerebral cortex, the portion of the
brain that controls higher level functioning, displays a two-layer pattern.
Receptor autoradiography shows high densities in layers I and IV and lower
densities in layers II and III (Herkenham et al., 1991; Mailleux & Vanderhaeghen,
1992). The hindbrain has low staining in the pons and medulla but intense
staining in the cerebellum (Matsuda et al., 1993). Within the cerebellum, which is
involved in motor coordination and movement, very dense CB1 binding can be

9

identified throughout the molecular layer of the cerebellar cortex, but sparse
labeling occurs in the cerebellar granular layer (Herkenham et al., 1991; Mailleux
& Vanderhaeghen, 1992). Furthermore, low densities of CB1 binding occur in
the corpus callosum, thalamus, hypothalamus, and midbrain (Egertová & Elphick,
2000; Matsuda et al., 1993; Tsou et al., 1998).
Despite earlier reports that CB2 receptors were only found in the
peripheral nervous system, the CB2 receptor has been discovered in brain areas
including the orbital, visual, motor, and auditory cortices (Gong et al., 2006).
Furthermore, CB2 receptors are found in the anterior olfactory nucleus and the
pyramidal neurons of the hippocampus, specifically, the CA2 and CA3 regions.
In addition, CB2 receptor staining was found in the thalamus, periaqueductal
gray, substantia nigra pars reticulata, midbrain and medulla. There is also
intense staining of the Purkinje cell bodies and moderate staining of their
dendrites in the cerebellum (Gong et al., 2006). Thus, CB2 receptors are found
in similar locations as the CB1 receptors; however, their distribution patterns and
densities within these regions differ (Gong et al., 2006).
Gestational Development
There are similarities and differences between the gestational CB receptor
system and the adult CB receptor system. The expression of CB1 receptor
mRNA has been measured in rats as early as gestational day (GD) 14
(Berrendero et al., 1998). Specific binding at GD 18 is detected in areas such as
the hippocampus, cerebral cortex, and cerebellum, which is similar to adults
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(Berrendero et al., 1998). CB1 receptor mRNA is detectable in the dentate gyrus
of the hippocampus by GD 16 and is localized in the subfields of the Ammon’s
horn by GD 21. CB1 receptor mRNA progressively increases in the cerebral
cortex from GD 16 to GD 21. By GD 21, CB1 receptor binding can be identified in
the basal ganglia, hippocampus, cerebral cortex, and cerebellum (Berrendero et
al., 1999). Interestingly, CB1 mRNA was measurable in the midbrain, pons, and
brainstem from GD 16 to GD 21 whereas these brain regions do not contain
cannabinoid receptors in adulthood (Berrendero et al., 1998; Herkenham et al.,
1991; Mailleux & Vanderhaeghen, 1992). The distribution of CB1 receptors
found in the corpus callosum, anterior commissure, fornix, fimbria, fasciculus
retroflexum, and the stria medullaris and terminalis are also inconsistent with the
distribution of CB1 receptors in adulthood (Berrendero et al., 1998; 1999;
Romero et al., 1997).
Postnatal Development
The distribution of CB1 receptors in early postnatal development is
consistent with the adult neuronal localization of CB1 receptors (Belue, Howlett,
Westlake & Hutchings, 1995). The densities of CB1 receptors in the basal
ganglia and limbic system steadily increase from PD 5 to adulthood (Berrendero
et al., 1999). On the other hand, binding levels in the caudate putamen, septum
nuclei, and nucleus accumbens appear to first decrease from GD 21 until birth,
before they begin to increase postnatally (Belue et al., 1995; Berrendero et al.,
1999). The striatal levels of CB1 receptors double from PD 0 to PD 7 and then

11

double again by PD 21 before reaching adult levels (Belue et al., 1995;
Berrendero et al., 1999). CB1 receptors located on external (II-III) and internal
(V-VI) layers of the cerebral cortex continue to increase at a consistent rate from
PD 21 until reaching adult levels (Berrendero et al., 1998; Berrendero et al.,
1999; Herkenham et al., 1991; Mailleux & Vanderhaeghen, 1992).
An increase in CB1 receptor levels across development is also observed
with receptor binding in the cerebellum and cortex, except that CB1 binding in the
cortex increases less from PD 14 to adulthood than in the striatum and
cerebellum (Belue et al., 1995). CB1 receptors in the hippocampus display a
gradual increase throughout development before reaching adult levels (Belue et
al., 1995). Lastly, the densities of CB1 receptors found in white matter areas,
such as the corpus callosum and sub-ventricular zone of the neocortex, during
gestational development, are no longer visible during postnatal development and
in adulthood (Berrendero et al., 1998; Berrendero et al., 1999; Romero et al.,
1997).
Cellular Signal Transduction
Stimulation of both CB1 and CB2 receptors causes the activation of
cellular signal transduction through Gi/o protein pathways (For reviews; see
Howlett, 2002; Pertwee, 1997). These receptors, when activated, cause the
inhibition of cyclic AMP formation. Through this inhibition, CB receptors
modulate intracellular cyclic AMP, which regulates ion channels via protein
kinase A (for reviews; see Howlett, 2002; Pertwee, 1997). CB receptors are
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coupled to inwardly rectifying potassium channels. Through the Gi/o protein
pathway, CB receptors inhibit voltage-gated calcium channels which increases
intracellular calcium (For reviews; see Howlett, 2002; Pertwee, 1997). CB
receptors also stimulate the phosphorylation of mitogen-activated protein kinase.
Lastly, CB1 and CB2 receptors facilitate immediate early gene expression and,
regulate protein synthesis (For reviews; see Howlett, 2002; Pertwee, 1997).
Cannabinoid Receptors and Neurotransmission
Activation of CB1 receptors on the presynaptic terminals inhibits the
release of both excitatory and inhibitory neurotransmitters (For review; see
Howlett et al., 2002). CB1 receptors are heavily involved in GABAergic inhibition
in the globus pallidus, substantia nigra and hippocampus (Maneuf, Crossman, &
Brotchie, 1996; Maneuf, Nash, Crossman & Brotchie, 1996; Hoffman & Lupica,
2000; Romero, De Miguel, Ramos & Fernández-Ruiz, 1997). Furthermore,
activation of cannabinoid receptors can also increase the release of other
transmitters. For example, dopamine release is stimulated in the nucleus
accumbens, ventral tegmental area, and substantia nigra by the activation of
CB1 receptors (Oleson & Cheer, 2012). In addition, when presynaptic CB1
receptors are activated there are increases in acetylcholine in the hippocampus
(Acquas, Pisanu, Marrocu & Di Chiara, 2000) and glutamate release in the
cerebral cortex (Ferraro et al., 2001). Overall, CB1 receptors modulate synaptic
transmission across the brain (Kreitzer, 2005).
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CHAPTER THREE
THE ENDOCANNABINOID SYSTEM:
ENDOGENOUS CANNABINOIDS
Once CB receptors were discovered, it was apparent that there were
endogenous ligands that must bind to these receptors. Anandamide was
identified first and named after the Sanskrit word for bliss because its effects
were similar to THC (Devane et al., 1992). Next, 2-AG was identified and was
found to be more abundant in the brain than anandamide (Stella, Schweitzer &
Piomelli, 1997). These two endocannabinoids are responsible for the stimulation
of CB receptors and the neuromodulatory actions of the endocannabinoid system
(For review, see Howlett, 2002).

Anandamide
Distribution
The distribution of anandamide in the brain coincides with the known
distribution of cannabinoid receptors (Bisogno et al., 1999; Felder et al., 1996).
Thus, rats have the highest levels of anandamide in the hippocampus, brainstem,
medulla, and striatum (Bisogno et al., 1999; Felder et al., 1996); whereas, low
levels of anandamide are found in the cerebellum, thalamus, diencephalon, and
cortex (Bisogno et al., 1999; Felder et al., 1996). The precursor for anandamide,
N-arachidonoyl phosphatidylethanolamine (NArPE), is also measured in high
concentrations in the brainstem, striatum, and hippocampus while low
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concentrations occur in the cerebellum. The levels of NArPE are much greater
than anandamide (Bisogno et al., 1999).
Synthesis and Release
Anandamide is created from free arachidonic acid and ethanolamine
(Sugiura et al., 1996). Anandamide is produced on demand and its biosynthesis
is controlled by intracellular calcium levels that activate phospholipase D and
catalyze NArPE hydrolysis (For review, see Basavarajappa, 2007, Cadas, Di
Tomaso & Piomelli, 1997; Di Marzo et al., 1994). NArPE activates Nacyltransferase (NAT), which causes the movement of an acyl group from
phospahatidylcholine to the ethanolamine portion of phosphatidylethanolamine,
thus producing N-acyl phosphatidylethanolamine (NAPE; Basavarajappa, 2007;
Cadas et al., 1997; Di Marzo et al., 1994,). Anandamide and phosphatic acid are
then released into the synaptic cleft after cleavage by NAPE specific
phospholipase D (For review, see Basavarajappa, 2007). It is unclear if the rate
limiting step is the cleavage by NAPE-specific phospholipase D or the activation
of NAT (Hansen, Hansen, Schousboe & Hansen, 2000; Maccarrone et al., 1998).
Metabolism
After the release of anandamide into the extracellular space, it
experiences selective and rapid uptake through the anandamide membrane
transporter (Deutsch et al., 2001). After anandamide is removed, intracellular
degradation occurs by enzymatic hydrolysis (Deutsch & Chin, 1993; Di Marzo et
al., 1994). The enzyme that causes anandamide hydrolysis, fatty acid amide
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hydrolase (FAAH), is properly known as arachidonoylethanolamide
amidohydrolase (Deutsch et al., 2001; Maccarrone & Finazzi-Agró, 2002). The
metabolism of anandamide occurs when FAAH breaks the amide bond, which
causes the release of arachidonic acid and ethanolamine (Deutsch et al., 2001;
Maccarrone & Finazzi-Agró, 2002).
Behavioral Effects
Anandamide can cause a wide range of behavioral effects. In rats, it
increases in the motivation to eat, frequency of eating, and food intake as well as
reduced eating latency are observed after injections of anandamide (Martın
́ ezGonzález et al., 2004; Williams & Kirkham, 2002). Sexual behavior also changes
when rats are given injections of anandamide. Specifically, the frequency of
ejaculation changes in a dose-dependent manner with a low dose decreasing
ejaculations and a high dose increasing ejaculation. Anandamide also reduces
pain in the formalin test (Guindon, De Léan, & Beauliue, 2006). In addition,
anandamide modulates sleep wake cycles by causing rapid eye movement and
slow-wave sleep II, which regulates alertness in rats (Murillo-Rodriguez et al.,
1998). Furthermore, anandamide and the exogenous cannabinoid THC affect
open field behavior similarly because both THC and anandamide decrease
grooming, rearing, and motor behavior while increasing periods of inactivity
(Romero et al., 1995).
Interestingly, both non-human primates and rats will intravenously selfadminister anandamide (Justinova, Solinas, Tanda, Redhi & Goldberg, 2005;
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Solinas, Justinova, Goldberg & Tanda, 2005). This self-administration behavior
is accompanied by an elevation of dopamine levels in the accumbens shell and
suggests that anandamide may have rewarding properties (Solinas et al., 2006).
Additionally, anandamide modulates the release of other neurotransmitters. For
example, anandamide decreases serotonin in the hippocampus and increase it in
the hypothalamus (Hao, Avraham, Mechoulam & Berry, 2000). Anandamide also
increases dopamine in the hippocampus and hypothalamus as well as increases
cortisol levels (Hao et al., 2000). Overall, anandamide modulates hunger, sexual
activity, alertness, and neurotransmission and, like THC, produces rewarding
effects (Guindon et al., 2006; Hao et al, 2000; Justinova et al., 2005; Kirkham &
Williams, 2001; Martın
́ ez-González et al., 2004; Romero et al., 1995; Solinas et
al., 2006;).

2-Arachidonoylglycerol
Distribution
Distribution of 2-AG has the highest levels in the brainstem and
hippocampus and moderate to high levels in the limbic forebrain and striatum
(Bisogno et al., 1999). The lowest levels of 2-AG are found in the hypothalamus,
cerebellum, and anterior pituitary (Bisogno et al., 1999; Sugiura & Waku, 2000).
Interestingly, 2-AG levels are found to fluctuate with the light/ dark cycle in rats
(Valenti et al., 2004).
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Synthesis and Release
The biosynthetic pathways of 2-AG include a few possible routes (For
review, see Basavarajappa, 2007). The first pathway is mediated by
phospholipase C hydrolysis to produce diacylglycerol which, in turn, is converted
into 2-AG by diacylglycerol lipase (Sugiura et al., 1995). The second possible 2AG biosynthesis route is through the hydrolysis of phosphatidylinositol from
phosphatidylinositol-specific phospholipase A1, which is converted into 2-AG by
lyso-phosphatidylinositol specific phospholipase C (Sugiura et al., 1995).
Therefore, it is clear that phospholipase C and diacylglycerol lipase are important
for 2-AG synthesis but it is unclear the main biosynthetic pathway.
Inactivation and Metabolism
The inactivation of 2-AG occurs by reuptake through the anandamide
membrane transporter and is then metabolized into 2-arachidonyl LPA by
monoacyl glycerol kinase, which is then converted into 1-stearoyl-2 arachidonoyl
PA (For review, see Basavarajappa, 2007).
Behavioral effects
Multiple behavioral and neurological functions are modulated by 2-AG.
Elevated levels of 2-AG have been found after head injury and this elevation may
help to reduce brain edema and hippocampal cell death and improve the level of
recovery (Panikashvili et al., 2001). 2-AG serves as the immediate response to
reduce inflammation (Berdyshev, Schmid, Krebsbach & Schmid, 2001) and 2-AG
inhibits invasive prostate cancer cells (Nithipatikom et al., 2004). Furthermore, 2-
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AG is involved in stress-related behaviors. For example, the formation of 2-AG is
triggered by stress and helps enhance stress-induced analgesia (Hohman et al.,
2005). 2-AG levels are also elevated after chronic stress exposure suggesting a
role in preventing the development of anxiety (Sumislawski, Ramikie, & Patel,
2011).
2-AG has been linked to the rewarding properties of stimuli such as food
and drugs. Mice given high fat diets show an increase in hypothalamic 2-AG,
which may increase the rewarding and reinforcing effects of the high fat diet
(Higuchi et al., 2012). Squirrel monkeys self-administer 2-AG, which shows that
it has reinforcing properties like drugs of abuse (Justinova, Yasar, Godfrey,
Redhi & Goldberg, 2011). Overall, 2-AG is a neuroprotectant and cancer growth
inhibitor, it has anti-inflammatory and analgesic properties, reduces stress, and
augments reward circuitry (Berdyshev et al., 2001; Higuchi et al., 2012; Hohman
et al., 2005; Justinova et al., 2011; Nithipatikom et al., 2004; Panikashvili et al.,
2001; Sumislawski et al., 2011; Vigano et al., 2003).
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CHAPTER FOUR
EXOGENOUS CANNABINOIDS
The cannabis plant includes over 70 chemicals that are responsible for the
psychoactive and medical properties experienced by the user (ElSohly & Slade,
2005). The actions of the chemical constituents in cannabis have been mimicked
and inhibited with synthetic compounds that can bind to CB1 and CB2 receptors
(Pertwee et al., 2010). Both plant and synthetic cannabinoids have allowed for a
more in-depth examination of the behavioral outcomes associated with CB
receptors and have given insight into the appeal of cannabis use recreationally
and medically.

Tetrahydrocannabinol
THC is the most commonly studied exogenous cannabinoid and produces
a wide range of actions. The psychological aspects of THC can be separated
into four categories: affective (euphoria), sensory (increased perception of
stimuli), somatic (body sensations), and cognitive (problems with concentration,
perception and time estimation; Perez-Reyes, 1999). The psychological and
physiological effects of THC have been thoroughly assessed. This cannabinoid
can influence cognition by altering perception and psychomotor performance as
well as regulate emotional states (For review, see Grotenhermen, 2007).
Futhermore, THC modulates functions of the nervous system, cardiovascular
system, hormonal system, immune system and respiratory system (For review,
see Grotenhermen, 2007)
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THC can be absorbed into the body via multiple routes of administration.
Inhalation is the most common way THC enters the human body (Agurell et al.,
1986). The bioavailability of inhaled THC ranges from 2-56% because there is
variability in the frequency and quantity of THC use depending on the individual.
After smoke inhalation, the blood plasma levels of THC peak quickly within
anywhere from 3 to 10 min (Huestis, 2005). In contrast, the oral administration of
THC has a much slower onset of effects and more erratic effects compared to
inhalation (Law, Mason, Moffat, Gleadle & King, 1984). The bioavailability of
THC taken orally is about 10-20% after it is absorbed into the gastrointestinal
tract and liver (Wall, Sadler, Brine, Taylor & Perez-Reyes, 1983). When
ingested, the effects of THC peak between 60 and 120 minutes and last an
average of 4-6 hr (Ohlsson et al., 1982).
As shown in rats, once absorbed into the body, THC binds to lipoproteins
and 90% of THC is found in blood plasma and 10% is found in red blood cells
(Fehr & Kalant, 1974). THC is primarily metabolized by cytochrome P450, with
over 80 different metabolites produced (Huestis, 2005; Sharma, Murthy &
Bharath, 2012). At low doses (16 mg), THC is eliminated from plasma within 3 to
6 hours whereas high doses (34 mg) can take 6-27 hr (Huestis, 2005). The halflife of THC is 25-26 hr but in heavy users the half-life can range from 19-53 hr
(Hunt & Jones, 1980; Wall, Sadler, Brine, Taylor & Perez‐Reyes, 1983). Within 5
days of use, up to 90% of THC has been eliminated from the body, over 65% is
excreted in the fecal matter, and around 25% through urine (Huestis, 2005; Wall
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et al., 1983). Overall, a single dose of THC can be detected in the body for up to
12 days, moderate use can be detected for around 30 days, and THC can be
detected up to 77 days in heavy users (Ellis, Mann, Judson, Schramm &
Tashchian, 1985). A lethal human dose of cannabis has not been reported but
an oral dose of 800-1900 mg/kg THC is lethal to rodents (Grotenhermen, 2007;
Thompson, Rosenkrantz, Schaeppi & Braude, 1973).
THC is a partial agonist of both CB1 and CB2 receptors, but with lower
efficacy for the CB2 than CB1 receptor (Howlett et al., 2002; Pertwee, 2008).
THC activates CB1 receptors located on presynaptic terminals in the central
nervous system, thus modulating the release of neurotransmitters glutamate,
GABA, dopamine and acetylcholine (Pertwee & Ross, 2002). These
neuromodulatory actions have been observed in the nucleus accumbens and
synaptic projections that extend to the ventral tegmental area, hippocampus, and
prefrontal cortex (Pertwee, 2008; Pertwee & Ross, 2002). In sum, THC is a nonlethal drug that takes an average of 30 days to be excreted from the body (Ellis
et al., 1985). This partial cannabinoid receptor agonist is involved in numerous
behavioral and neurological processes that induce reward as well as medical
value.

Cannabidiol
The plant cannabinoid, cannabidiol (CBD), does not produce the euphoric
effects observed with THC but it can have a wide range of effects, including
antipsychotic, antiepileptic, anxiolytic, and anti-inflammatory actions (Izzo,
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Borrelli, Capasso, Di Marzo & Mechoulam, 2009). Inhalation of CBD has an
average bioavailability of 31% after a single use (Ohlsson et al., 1986). CBD
binds to CB1 and CB2 receptors where it acts as both an antagonist and inverse
agonist (Pertwee, 2008; Thomas et al., 2007) and inhibits the effects of the
synthetic cannabinoid agonists CP55940 and R-(+)-WIN 55,212 (Pertwee et al.,
2002). CBD has therapeutic value for the treatment of symptoms associated with
cancer, arthritis, anxiety, diabetes, and immune disorders (For review, see
Mechoulam, Peters, Murillo-Rodriguez & Hanuš, 2007). Overall, CBD has value
as a medical treatment for a variety of ailments without the psychoactive sideeffects experienced with THC.

Synthetic Cannabinoids
Synthetic cannabinoids such as CP, HU-210, and R-(+)-WIN 55,212 bind
to both CB1 and CB2 receptors and have been used to characterize the CB1
receptor system (For review, see Howlett et al., 2002). These synthetic CB
receptor agonists have similar behavioral effects as THC and endogenous
cannabinoids including hypothermia, analgesia, catalepsy, and locomotor
suppression (Tai & Fantegrossi, 2014). These agonists modulate
neurotransmission by inhibiting GABA release in the substantia nigra and
hippocampus whereas synthetic cannabinoids increase acetylcholine in the
hippocampus, dopamine in the nucleus accumbens, and glutamate in the
cerebral cortex (For review, see Howlett et al., 2002). Overall, synthetic
cannabinoid agonists have similar physiological and behavioral effects as THC.
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CB antagonists, such as SR14716A, AM281, and LY320135, block the
effects of the CB receptor system (Pertwee, 2005). The antagonist AM281 can
reduce food intake in rats, increase locomotor activity in mice, and increase
glutamate release in the cerebellum (Pertwee, 2005). In contrast, LY320135
blocks the effects of CB receptor agonists and works as an inverse agonist in the
CB1 signal transduction pathway (Howlett et al, 2002). The most studied
antagonist is SR14716A because this potent CB1 ligand is able to inhibit CB
receptor agonists as well as reverse the effects of the CB1 and CB2 receptors
(Howlett et al, 2002). The behavioral effects that are observed with SR14716A
include enhanced locomotor activity, hyperalgesia, and pro-inflammatory
responses (Pertwee, 2005). SR14716A increases the release of acetylcholine,
epinephrine, and GABA in the hippocampus as well as increase glutamate in the
prefrontal cortex and striatum (Pertwee, 2005). Overall, these antagonists
reverse the actions of the cannabinoid system.
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CHAPTER FIVE
BEHAVIORAL SENSITIZATION
The prevalence of cannabis use disorder has led to the conclusion that
cannabis has addictive properties (Hasin et al., 2015). Therefore, it is important
to have a better understanding of how cannabis alters behavior and leads to
compulsive drug taking. Animal models, including self-administration, drug
discrimination, conditioned place preference, and behavioral sensitization, have
been invaluable tools for studying the addictive properties of drugs such as
cannabis (Maldonado & de Fonseca, 2002; Sanchis-Segura & Spanagel, 2006).
In particular, behavioral sensitization examines incentive value or “craving” for a
given drug (For reviews, see Robinson & Berridge, 1993, 2000, 2001, 2003;
Steketee & Kalivas, 2011).
Behavioral sensitization is a phenomenon in which prior exposure to a
drug leads to an enhanced behavioral response to later administration of that
drug (For reviews, see Robinson & Berridge, 1993, 2000, 2001, 2003; Steketee
& Kalivas, 2011). In animals, this occurs through the process of induction, or the
pre-exposure phase, in which the animal is exposed to the drug either once or
numerous times; and expression, or the test phase, when the animal is exposed
to the drug after a period of abstinence (For reviews, see Robinson & Berridge,
1993, 2000, 2001, 2003; Steketee & Kalivas, 2011). Behavioral sensitization can
be assessed by monitoring changes in stereotyped and non-stereotyped
behaviors during both the induction and expression phases (For reviews, see
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Robinson & Berridge, 1993, 2000, 2001, 2003; Pierce & Kalivas, 1997; Steketee
& Kalivas, 2011). Stereotyped behaviors include actions such as gnawing,
licking, and undirected sniffing whereas non-stereotyped behaviors include
exploratory sniffing, locomotor activity, and rearing (Rubino, Viganò, Massi &
Parolaro, 2001). Sensitization can be affected by associative processes such
that the enhanced behavioral effect is stronger or exclusively observed when the
animal is tested in the same environment in which the drug was initially given
(For review, see Robinson, Browman, Crombag & Badiani, 1998). This type of
sensitization is referred to as context-dependent sensitization whereas
sensitization that is apparent without a consistent context is known contextindependent sensitization (For review, see Robinson et al., 1998).

Adult Sensitization
Dose-dependence
Sensitization can be dependent on the amount of drug that is given. For
example, psychostimulants cause a dose-dependent enhanced behavioral
response such that low doses of psychostimulants produce sensitization but the
intensity of the sensitized behavior becomes more robust with higher doses
(Browman, Badiani, & Robinson, 1998a, 1998b; Davidson, Lazarus, Lee &
Ellinwood, 2002; Frantz, O’Dell, & Parsons, 2007).
Multi-trial vs. Single-trial Sensitization
An enhanced behavioral response may occur after a number of preexposures or only one pre-exposure to a drug. Both psychostimulant induced
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multi-trial and single-trial sensitization have been extensively examined. During
multi-trial sensitization, the animal is pretreated with the drug repeatedly over a
period of time (typically at daily intervals) and then examined for changes in
behavior after an abstinence period (for reviews, see Pierce & Kalivas, 1997;
Steketee & Kalivas, 2011). The sensitized response in single-trial sensitization
tends to require a relatively high dose of the drug (Battisti, Chang, Uretsky &
Wallace, 1999; Fontana, Post & Pert, 1993). The expression of the sensitized
response can persist long after the animal has been exposed to the drug (Leith &
Kuczenski, 1982). This enhanced behavioral responsiveness after one or many
drug exposures may be relevant to drug relapse and the continuation of drug use
(Robinson & Berridge, 1993).
Psychostimulant induced multi-trial sensitization can been seen after
short and long periods of abstinence. For example, adult rats given cocaine for 4
consecutive days show a sensitized response 48 hr later (Laviola, Wood, Kuhn,
Francis & Spear, 1995). Sensitization to 5 days of repeated cocaine exposure is
observed in adult rats after a 3 week abstinence period (Ujike, Tsuchida,
Akiyama, Fujiwara, & Kuroda, 1995). Furthermore, the persistence of multi-trial
sensitization can also be seen after a 12 week abstinence period when
pretreated for 6 days with amphetamine (Leith & Kuczenski, 1982).
Nonetheless, multiple days of pre-exposure are not necessary to cause
an enhanced behavioral response because adult rats given a single pretreatment
injection of cocaine show a sensitized response to the drug 24 hr later
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(McDougall, Baella, Stuebner, Halladay & Crawford, 2007). This can also be
observed in adult mice when given single pretreatment injection of amphetamine
and examined for sensitization 24 hr later (Battisti et al., 1999). Although the
persistence of single-trial psychostimulant sensitization is not as apparent as is it
with multiple exposures, mice exposed to single injection of methamphetamine
have shown a sensitized response up to 21 days after exposure (Jing et al.,
2014).
Context-dependent vs. Context-independent Sensitization
Differences in sensitization occur depending on the environment in which
the drug was given (For review, Robinson et al., 1998). Multi-trial behavioral
sensitization is stronger when the induction and expression of psychostimulant
sensitization are conducted in the same environment but is apparent if the
environments are not the same (For review, Robinson et al., 1998). Adult rats
given psychostimulants show context-independent sensitization although it is not
as robust as with context-dependent sensitization (Crombag, Badiani, Maren &
Robinson, 2000; Badiani, Browman & Robinson, 1995; Browman et al., 1998a;
1998b; Laviola et al., 1995). This demonstrates that the enhanced behavioral
response associated with multi-trial sensitization is sensitive to, but not
dependent on, the context that the drug is given in (Crombag et al., 2000;
Baldiani et al., 1995; Laviola et al., 1995). One-trial sensitization, however, is
completely context-dependent in adult rats (McDougall et al., 2007). This means
that a single pre-exposure to a psychostimulant, such as cocaine, will not cause
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behavioral sensitization if the rat is challenged with cocaine in a different
environment (Fontana, Post & Pert, 1993; McDougall et al., 2007; Weiss, Post,
Pert, Woodward & Murman, 1989). Therefore, the associative context of drug
exposure modulates the intensity of the sensitized response in adult rats.

Adolescent Sensitization
Multi-trial vs. Single-trial Sensitization
Multi-trial psychostimulant induced behavioral sensitization is also
apparent early adolescent (PD 28) and late adolescent (PD 42) rats (Caster,
Walker & Kuhn, 2005). Specifically, when these male Sprague-Dawley rats are
exposed to escalating doses of cocaine both age groups express sensitization
after multiple drug exposures but early adolescent animals show a more robust
sensitization compared late adolescent rats (Caster et al., 2005). Adolescent
animals also display gender differences after repeated treatment with the
psychostimulant methylphenidate, as Sprague-Dawley female rats show
enhanced locomotor activity compared to males (Chelaru, Yang & Dafny, 2012).
Furthermore, repeated exposure to cocaine during adolescence causes a
persistent sensitized response that can be observed after a short (PD 37) and/or
long (PD 64) abstinence period (Marin, Cruz & Planeta, 2008).
The effects of psychostimulants using one trial sensitization are similar to
what has been observed with multiple trial sensitization during adolescent
development. Young rats (PD 19) given a single pretreatment injection of
cocaine show a sensitized locomotor response for up to 5 days after initial drug
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exposure (McDougall et al., 2009). Both early adolescent (PD 28) and late
adolescent (PD 42) rats show a sensitized behavioral response to a single high
dose of cocaine, although this response is more robust in the younger animals
(Caster, Walker & Kuhn, 2007). Additionally, amphetamine sensitization is
observed in early adolescent rats (PD 30) when tested 2 or 30 days later (PD 60;
Mathews, Kelly & McCormick, 2011). Overall, psychostimulant induced
behavioral sensitization is observed in pre-adolescent and adolescent rats using
both single-trial and multi-trial procedures.
Associative vs Non-associative Sensitization
Context is not as important for sensitization in young rats as it is in adult
rats. Preweanling rats (PD 19) given a single pretreatment injection of cocaine
show both context-dependent and context-independent sensitization for up to 5
days with a 10 mg/kg challenge of cocaine (McDougall et al., 2007). In fact,
these young rats actually showed stronger sensitization in a context-independent
environment relative to a context-dependent environment (McDougall et al.,
2007). Stronger sensitization in a context-independent environment can be seen
1 and 3 days after exposure (McDougall et al., 2009).
Although young rats experience context-independent sensitization after a
short abstinence period, environmental conditioning is important for sensitization
in these pups after a longer drug-free period (Zavala, Nazarian, Crawford &
McDougall, 2000). Specifically, rat pups pretreated for 5 days with cocaine only
show context-dependent sensitization after a 7-day drug free period; whereas,
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after 1 day of abstinence, preweanling pups show both context-independent and
context-dependent sensitization (Zavala et al., 2000).

Behavioral Sensitization using Cannabinoids
Although behavioral sensitization has become a common tool for studying
abused drugs, relatively little sensitization research has been conducted with
cannabinoids. This is especially true when examining early and late adolescent
rats. Cannabinoids, like psychostimulants, can produce behavioral sensitization
that persists after the discontinuation of drug use (Rubino et al., 2001). In the
first report of cannabinoid multi-trial sensitization, adult Sprague-Dawley male
rats were pretreated with THC twice a day for 5 days (Rubino et al., 2001). All
animals received a dosage regimen in which the amount of THC administration
increased over the 5-day period (5, 10, 20, 40 and 40 mg/kg) and sensitization
was assessed after a long abstinence period of 20 days (Rubino et al., 2001).
Pretreatment with THC sensitized behaviors associated with stereotyped activity
including gnawing, licking, and undirected sniffing after a 5 mg/kg THC challenge
injection. Furthermore, a trend was noticed in non-stereotype activities, including
a slight increase in forward locomotion, sniffing, and rearing (Rubino et al., 2001).
Different patterns of sensitization occur depending on the length of
exposure and the dose of THC administered. After 3 days of an increasing THC
regime (2, 4, and 8 mg/kg), adult male Sprague-Dawley rats exhibited enhanced
non-stereotyped activity when challenged 14 days later with THC (150 μg/kg
intravenous; Cadoni, Pisanu, Solinas, Acquas & Chiara, 2001; Cadoni, Valentini
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& Di Chiara, 2008). This enhancement may have occurred due to the short
exposure period to THC and short abstinence period (Cadoni et al., 2001;
Cadoni, Valentini & Di Chiara, 2008). Overall, pretreatment with THC can cause
changes to both non-stereotyped and stereotyped behaviors that are associated
with an increased sensitized response to the drug.
Like THC, the synthetic cannabinoid agonist WIN 55,212-2 can cause the
induction of behavioral sensitization after a single exposure or multiple exposures
(Enayatfard et al., 2013). Specifically, an enhanced behavioral response to WIN
55,212-2 was seen after a single pretreatment administration of a low dose (0.1
kg/mg, IP) when compared to saline-pretreated rats. After a 10-day regimen of
WIN 55,212-2 pretreatment rats also showed a sensitized response that
persisted 48 hr after the final pretreatment day (Enayatfard et al., 2013).
Furthermore a single exposure to WIN at a low dose has been shown to increase
locomotor responses whereas a single exposure to a high dose of WIN did not
enhance motor activity in the open field test (Drews et al., 2005).
Cross-sensitization with Other Drugs
Interestingly, the ability of cannabinoids to cross-sensitize with other drugs
has been examined more thoroughly than it has been for cannabinoid-induced
sensitization. For example, in adults, a single pre-exposure to either THC or WIN
55,212-2 increases sensitization to amphetamine when given 30 min later
(Gorriti, de Fonseca, Navarro & Polomo, 1999; Muschamp & Siviy, 2002). Also,
multiple exposures of THC or WIN 55,212-2 increases the sensitized response to
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amphetamine (Gorriti et al., 1999; Muschamp & Siviy, 2002). WIN 55,212-2,
when acutely injected, affects both ambulatory and rearing activity of animals that
are given amphetamine 30 min later (Muschamp & Siviy, 2002). When these
adult rats are exposed to WIN 55,212-2 for 10 days, an increase in ambulatory
movement and rearing activity is observed after a challenge injection of
amphetamine (Muschamp & Siviy, 2002). Additionally, adult rats treated with
morphine show an increased behavioral response when pretreated with a low or
high dose of either THC or CP (Cardoni et al., 2001; Cardoni et al., 2008;
Norwood, Cornish, Mallet & McGregor, 2003).
Ontogeny of Cannabinoid Sensitization
Unfortunately, very limited research has been conducted on the ontogeny
of cannabinoid sensitization. At present, it is unknown whether cannabinoid
sensitization, like psychostimulant sensitization, would differ between adolescent
and adult rats. Interestingly, there has been one investigation that showed, that
an 8-day THC pretreatment induced a sensitized response to a cocaine
challenge in late adolescent rats but not in adult rats (Dow-Edwards &
Izenwasser, 2012).
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CHAPTER SIX
SUMMARY THESIS STATEMENT
Both the medical and recreational use of cannabis are now decriminalized
in California and many other states. Since the change in these state laws, there
has been surges in the availability and use of cannabis (Cerdá, Wall, Keyes,
Galea & Hasin, 2012; Hasin et al., 2015). A major concern with the rise in
societal acceptance of cannabis and the increased availability of this drug is
higher use rates in adolescent populations (Kosterman, Hawkins, Guo, Catalano,
& Abbott, 2000). Escalation of cannabis use in adolescents is important because
the risk of developing cannabis use disorder is stronger in people who start drug
use early (Richter, Pugh & Ball, 2016). The use of cannabis before the age of 15
increases the likelihood of becoming a chronic user and enhances the probability
of experimenting with other illicit drugs (Nelson, Van Ryzin, & Dishion, 2015;
Prince van Leeuwen et al., 2014; Richter et al., 2016). Moreover, adolescent use
of cannabis can cause long-term consequences, including problems with
executive functioning, that are not apparent in users that begin after the age of
15 (Fontes et al., 2011).
The cause for the inflation in problematic cannabis use with early onset is
unknown but an increase in the addictive properties of cannabis during this
developmental period may partially account for this. To this end, the present
thesis focused on the adolescent response to cannabis using the behavioral
sensitization paradigm. Behavioral sensitization is an animal model used to study
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craving, which is an important component of drug addiction (Berridge &
Robinson, 1995; For reviews, see Robinson & Berridge, 1993, 2000, 2001,
2003). In this model, drugs with addictive properties induce an augmented
behavioral response in animals after prior exposure to the drug (for reviews, see
Robinson and Berridge, 1993, 2000, 2001, 2003; Steketee & Kalivas, 2011).
Behavioral sensitization can be measured as changes in stereotypical and nonstereotypical behaviors (For reviews, see Steketee & Kalivas, 2011; Pierce &
Kalivas, 1997). Behavioral sensitization is sensitive to changes in environmental
contexts, number of drug pre-exposures, and developmental stage.
Currently, no studies have examined developmental differences in
behavioral sensitization to cannabinoids and very little data exists on the acute
effects of cannabinoids adolescence (For reviews, see Jacobus & Tapert, 2014;
Viveros, Llorent, Moreno, & Marco, 2005). Thus, the purpose of this thesis was
to examine the effects of the cannabinoid agonist CP in early adolescent
Sprague-Dawley rats (PD 30-36) using the behavioral sensitization paradigm. CP
was used because it mimics the effects of THC, the primary psychoactive
ingredient in cannabis (Gurney, Scott, Kacinko, Presley & Logan, 2014).
Specifically, this study assessed the ability of CP to induce behavioral
sensitization in adolescent rats and determine if there are gender differences in
the sensitization to CP. In addition, we also examined the ability of CP to induce
cross-sensitization to cocaine in adolescent rats.
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Despite the limited data available on developmental sensitization to
cannabinoids, the following four hypotheses were formulated:
1. Repeated treatment with CP would induce a sensitized behavioral
response in male and female adolescent rats.
As mentioned above, there is limited data on the response of adolescent
rats to cannabinoid agonists. However, based on the adult literature assessing
behavioral sensitization with cannabinoid agonists (Cadoni et al., 2001; Cadoni et
al., 2008; Enayatfard et al., 2013; Rubino et al., 2001) and literature showing that
adolescent rats are more often more sensitive to drug exposure than adults (For
review, see Izenwasser, 2005), it was predicted that repeated treatment with the
CP compound would result in a augmented behavioral response in adolescent
rats.
2. Female adolescent rats would show a greater behavioral response to CP
than male adolescent rats.
Gender differences are common in the behavioral response to drugs of
abuse. Adult female rats are more sensitive to the behavioral effects of
cannabinoids because female rats given either THC or CP have a greater
antinociceptive response, show increased catalepsy, and display more
spontaneous locomotor activity compared to male rats (Tseng & Craft, 2001).
Additionally, female rats display greater sensitization to psychostimulants
(Chelaru et al., 2012). Based on the evidence that female rats display greater
sensitivity to cannabinoids in other behavioral measures using cannabinoids and
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show enhanced behavioral sensitization to psychostimulants, it was
hypothesized that female rats would show stronger behavioral sensitization to the
cannabinoid agonist CP than male rats.
3. Cocaine would induce behavioral sensitization and conditioned activity in
both male and female adolescent rats.
Cocaine-induced sensitization and conditioned activity are both well
documented phenomenon in rats. Cocaine sensitization can be observed in rats
as early as PD 19 and has been previously demonstrated in adolescent rats
(Caster et al., 2005, 2007; McDougall et al., 2007, 2009). In contrast,
conditioned activity is not found in preweanling and preadolescent rats but is
quite robust and persistent in adult rats (McDougall et al., 2014). Based on this
literature, it was expected that adolescent rats would show a cocaine sensitized
response. We also believed that both the male and female adolescent rats
would respond in an adult like manner and show conditioned activity.
4. Repeated treatment with CP would induce a sensitized response to
cocaine.
Early adolescent exposure to cannabis increases the likelihood of using other
drugs of abuse in human adolescents (Haberstick et al., 2014; Peer et al., 2013;
Farmer et al., 2015). The reason for this increased vulnerability is unclear as it is
not known whether environmental/social issue drive the increased drug use or
changes in neuronal functioning after cannabis exposure. In adult and later
adolescent rats there is data showing that exposure to THC or WIN can cause a
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sensitized response amphetamine, cocaine and morphine (Dow-Edwards &
Izenwasser, 2012; Cardoni et al., 2001; Cardoni et al., 2008; Gorriti et al., 1999;
Muschamp & Siviy, 2002). We predicted that early adolescent rats given
repeated injections of CP would also show a sensitized response to cocaine.
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CHAPTER SEVEN
MATERIALS AND METHODS
Subjects
Male and female rats (N = 283) of Sprague-Dawley descent (Charles
River; Hollister, CA) were used. Rats were in early adolescence at the time of
pretreatment (PD 30- PD 34) and testing (PD 36). All rats were bred and raised
in the vivarium of the Psychology Department of California State University, San
Bernardino. Dams and pups were housed in maternity cages that were large
polycarbonate clear boxes (56 × 34 × 22 cm) with a wire lid. Litters were culled
on PD 3 to 10 pups per dam and pups were group housed (3-4 per cage) away
from dams on PD 23. All cages had Tek-Fresh® bedding (Harlan, Indianapolis,
IN). All animals received food and water ad libitum and kept on a12 hour light
and 12 hour dark cycle. Behavioral testing took place during the light cycle with
subjects returned to their home cage after testing. All subjects were handled
according to the “Guide for the Care and Use of Laboratory Animals” (National
Research Council, 2010) under a research protocol approved by the Institutional
Animal Care and Use Committee of California State University, San Bernardino.
Apparatus
All behavioral testing was performed in commercially available activity
monitoring chambers (41 × 41 × 41 cm) from Coulbourn Instruments (Allentown,
PA, USA). These chambers were kept in a separate testing room away from the
animal colony. The activity chambers consist of four acrylic walls, a gray plastic
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floor, and an open top. To measure horizontal locomotor activity or distance
traveled, each chamber included an X-Y photobeam array with 16 photocells and
detectors with a photobeam resolution of 0.76 cm. The position of each rat was
determined every 100 ms (i.e., the sampling interval). Each chamber was
equipped with a video camera centered above the chamber.
Drugs
CP and cocaine were purchased from Sigma Aldrich (St. Louis, MO). The
CP drug was mixed in a 50% dimethyl sulfoxide (DMSO)/ water solution and
cocaine was mixed in saline. All injections were given intraperitoneally (IP) at a
volume of 1.0 ml/kg.
Procedure and Statistical Analysis
Experiment 1. Effect of Dose on CP-induced Multi-trial Sensitization in
Early Adolescent Male and Female Rats. Adolescent rats (N= 137) were given
five pretreatment days (PD 30-PD 34), a 48 hr abstinence period, and one test
day (PD 36; see Table 1). During pretreatment, rats were given CP (4, 13.2, or
40 µg/kg, IP) or vehicle in the testing room and then placed immediately into the
activity chambers. Following a 10 min habituation period, distance traveled and
stereotyped movements were measured for 60 min. After the 48 hr abstinence
period, half of the rats in each drug group received 4 µg/kg CP and the other half
received 13.2 µg/kg CP. Test day injections of CP were given in the testing room
and rats were placed in activity chambers for 120 min. Similar to the conditioning
days, behavioral monitoring began after a 10 min habituation period.
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Table 1.
Experiment 1 Design and Timeline
Pretreatment
age
Male or
Female

PD 30-PD 34

Pretreatment doses
CP 55,940
0, 4, 13.2 or 40
µg/kg

Test age

Test dose of
CP 55,940

PD 36

4 or 13.2 µg/kg

Experiment 1 Analyses. Distance traveled and repetitive movement data
for the pretreatment sessions were analyzed by separate three-way (sex ×
pretreatment drug × day) mixed factorial ANOVAs. Test day data was analyzed
by separate four-way (sex × pretreatment drug × test day drug × time block)
mixed factorial ANOVAs. Significant higher-order interactions were further
analyzed using two- or one-way ANOVAs. Post hoc analysis were made using
Tukey tests (p < 0.05). Litter effects were controlled through experimental
design, with no more than one subject per litter being assigned to a particular
group.
Experiment 2. Cross-sensitization between CP 55,940 and Cocaine in
Early Adolescent Male and Female Rats. Adolescent rats (N= 146) were given
five pretreatment days (PD 30- PD 34), a 48 h abstinence period, and one test
day (PD 36), (see Table 2). The CP pretreatment doses (13.2 or 40 µg/kg) were
determined from Experiment 1, cocaine (20 mg/kg) and vehicle (DMSO or
Saline). All rats were given one daily IP injection in the experimental chamber.
After rats received their injection in the experimental room they were placed in
activity chambers. After a 10 min habituation period distance traveled and
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stereotyped movements were measured for 60 min. On the test day (PD 36), all
animals received an IP injection of cocaine (10 mg/kg) or saline and after 10 min
distance traveled and stereotyped movement were measured for 120 min.

Table 2.
Experiment 2 Design and Timeline
Pretreatment
age
Male or
Female

PD 30- PD 34

Pretreatment dose
13.2 µg/kg CP 55,940
40 µg/kg CP 55,940
20 mg/kg Cocaine
Vehicle

Test
age
PD 36

Test dose
10 mg/kg
Cocaine
Saline

Experiment 2 Analyses. Distance traveled and stereotyped movement
data for the pretreatment sessions were analyzed by separate three-way (sex ×
pretreatment drug × day) mixed factorial ANOVAs. Test day data was analyzed
by separate four-way (sex x pretreatment drug× test drug × time block) mixed
factorial ANOVAs. Significant higher-order interactions were further analyzed
using two- or one-way ANOVAs. Post hoc analysis of data was made using
Tukey tests (p < 0.05). Litter effects were controlled through experimental
design, with no more than one subject per litter being assigned to a particular
group.
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CHAPTER EIGHT
RESULTS
Experiment 1 examined the dose-response relationship of cannabinoidinduced sensitization. It was predicted that female rats would display an overall
greater sensitivity to the cannabinoid doses and that both males and females
would show cannabinoid induced sensitization through increased distance
traveled and stereotyped movement.
During the pretreatment period a significant main effect of sex was
observed in distance traveled scores, F(1,127) = 5.478, p = .02. Specifically,
females had greater distance traveled scores compared to their male
counterparts. However, there was no significant main effect of sex in
stereotyped movement, F(1,127) = 3.128, p = .11 (Fig. 1). There was also a
trend for a main effect of conditioning drug for distance traveled, F(3,127) =
2.485, p = .06. This trend was primarily between the vehicle and 40 μg/kg CP
group, as animals treated with the high cannabinoid dose showed less activity
than rats given vehicle. There was no main effect of the conditioning drug
observed in stereotyped movement, F(3,127) = 2.076, p = .11. Lastly, no
interaction occurred between sex and conditioning drug for distance traveled,
F(3,127) = 1.400, p = .25 or stereotyped movement, F(3,127) = 0.934, p = .43. In
summary, there was no difference in the behavioral response of rats given
cannabinoids or vehicle during the conditioning phase (Fig. 2).
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Figure 1. Experiment 1 Conditioning Days by Gender
Mean distance traveled scores (± SEM) and stereotyped movements (± SEM) of
male and female adolescent rats injected with CP 55,940 (4, 13.5, 40 μg/kg, IP)
or vehicle and placed in photobeam activity chambers for five conditioning days
(PD 30-34). Data on this graph were collapsed across conditioning drug group. A
Indicated a significant difference from male rats over the 5 day conditioning
phase.
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Figure 2. Experiment 1 Conditioning Days by Conditioning Drug
Mean distance traveled scores (± SEM) and stereotyped movements (± SEM) of
male and female adolescent rats injected with CP 55,940 (4, 13.2, 40 μg/kg, IP)
or vehicle and placed in photobeam activity chambers for 5 conditioning days
(PD 30-34).

On the test day, treatment with CP differentially altered stereotyped
movements, F(1,121) = 7.58, p < 0.001, as rats treated with the low dose of CP
(4 μg/kg) had more stereotyped movements (M = 683.81, SEM = 29.14) than rats
given the higher dose of CP (13.2 μg/kg) (M = 570.73, SEM = 26.42). Distance
traveled scores did differ for the two CP drug doses, F(1,121) = 2.755, p = 0.10
(figure not shown). Pretreatment with CP at all doses failed to significantly
enhance distance traveled scores, F(3,121) = 1.099, p = 0.35, or stereotyped
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movements, F(3,121) = .753, p = 0.52 on the test day. Lastly, there was no
interaction between sex, condition drug and test day drug for distance traveled,
F(3,121) = .878, p = 0.45; (Fig. 3) or stereotyped behaviors, F(3,121) = .581, p =
0.63 (Fig. 4). These results indicate that cannabinoid pre-exposure did not
increase the behavioral response to a cannabinoid agonist in either female or
male adolescent rats.
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Figure 3. Experiment 1Test Day Distance Traveled
Mean distance traveled scores (± SEM) of male and female adolescent rats
injected with CP 55,940 (4, 13.2, 40 μg/kg, IP) or vehicle and placed in
photobeam activity chambers on the five conditioning days (PD 30-34) and then
challenged with CP 55,940 (4 or 13.2 μg/kg, IP) on test day (PD 36).
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Figure 4. Experiment 1 Test Day by Stereotyped Movement
Mean stereotyped movements (± SEM) of male and female adolescent rats
injected with CP 55,940 (4, 13.2, 40 μg/kg, IP) or vehicle and placed in
photobeam activity chambers on the five conditioning days (PD 30-34). On PD
36, rats were injected with (4 or 13.2 μg/kg, IP) and placed in photobeam activity
chambers for 2 h.

Experiment 2 examined conditioned activity and behavioral sensitization in
adolescent rats after pretreatment with either cocaine or CP and then a challenge
injection of cocaine or vehicle. During the pretreatment phase, the conditioning
drug significantly altered distance traveled scores, F(3,131) = 561.359, p< .001
and stereotyped movement, F(3,131) = 160.957, p < .001. That is, male and
female rats given cocaine had greater activity levels than rats treated with CP (40
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or 13.2 ug/kg) or vehicle (Tukey test, p < .01). The increase in stereotyped
movement occurred across all 5 days of conditioning (conditioning drug × day
interaction), F(9,413) = 8.021, p < .001. In contrast, conditioning drug effects
were not altered by day for distance traveled, F(8,364) = 1.760, p = .08 (Fig. 5).
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Figure 5. Experiment 2 Conditioning Days by Conditioning Drug
Mean distance traveled scores (± SEM) and stereotyped movements (± SEM) of
adolescent rats injected with CP 55,940 (13.2 or 40 μg/kg), cocaine (20 mg/kg) or
vehicle and placed in photobeam activity chambers on the five conditioning days
(PD 30-34). A Indicates a significant difference in activity for cocaine-pretreated
animals compared to CP 55,940 and vehicle-treated animals.
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On the test day, treatment with the test drug differentially altered distance
traveled scores, F(3,129) = 91.575, p < .001 and stereotyped movements
F(3,129) = 110.520, p < .001. Specifically, rats challenged with cocaine
displayed significantly more locomotor activity compared to rats challenged with
vehicle. This enhancement in activity remained significant across all 24 time
blocks for both distance traveled, F(3, 366) = 30.132, p < .001, and stereotyped
movement, F(6,775) = 7.652, p <.001 (Fig. 6).
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Figure 6. Experiment 2 Test Day by Test Drug
Mean distance traveled scores (± SEM) and stereotyped movements (± SEM) of
male and female adolescent rats injected with CP 55,940 (13.2 or 40 μg/kg, IP),
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cocaine (20 mg/kg, IP) or vehicle and placed in photobeam activity chambers on
five conditioning days (PD 30-34). On PD 36, rats were injected with cocaine (10
mg/kg, IP) or vehicle and placed in photobeam activity chambers for 2 h. Data in
this graph were collapsed across conditioning drug group. A Indicated a
significant difference between cocaine- and saline- challenged animals on the
test day.

Rats given saline on the test day were analyzed separately to assess
conditioned activity. Both distance traveled scores, F(3,57) = 10.49, p <.001 and
stereotyped movement, F(3,57) = .59, p < .001 were altered depending on the
conditioning drug given. Specifically, rats pretreated with cocaine had
significantly greater locomotor activity than vehicle-pretreated rats (Tukey test, p
< .01). Pretreatment with the CP drug did not alter saline-induced activity (Fig.
7). Sex did not alter the behavior of rats given saline on the test day for distance
traveled, F(3,57) = 1.31, p = .25 or stereotyped movements, F(3,57) = 1.87, p =
.17.
Rats given cocaine on the test day showed significant differences in
distance traveled, F(3,72) = 3.16, p = .03 and stereotyped behaviors, F(3,72) =
3.05, p =. 03 depending on the conditioning drug given because, rats pretreated
with cocaine had significantly greater distance traveled scores and stereotyped
movements compared saline-pretreated rats (Tukey test, p < .01; Fig. 8). Sex
did not significantly alter either distance traveled F(3,72) = 1.80, p = .18 or
stereotyped movements, F(3,72) = .02, p = .88 of rats given cocaine on the test
day. In contrast to cocaine-pretreated animals, rats pretreated with CP (13.2 or
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40 μg/kg) did not have significantly enhanced distance traveled scores (Tukey
test, p > 0.05) and stereotyped movement (Tukey test, p > 0.05) compared to
vehicle-pretreated animals on the test day (Fig. 7 and 8).
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Figure 7. Experiment 2 Test Day Saline by Conditioning Drug.
Mean distance traveled scores (± SEM) and stereotyped movements (± SEM) of
adolescent rats injected with CP 55,940 (13.2 or 40 μg/kg, IP), cocaine (20
mg/kg, IP) or vehicle and placed in photobeam activity chambers on five
conditioning days (PD 30-34). On PD 36, rats were injected with saline and
placed in photobeam activity chambers for 2 h. *Indicates significant difference
between cocaine-treated rats and rats treated with either saline or CP 55,940.
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Figure 8. Experiment 2 Test Day Cocaine by Conditioning Drug
Mean distance traveled scores (± SEM) and stereotyped movements (± SEM) of
adolescent rats injected with CP 55,940 (13.2 or 40 μg/kg, IP) cocaine (20 mg/kg,
IP), or vehicle and placed in photobeam activity chambers on five conditioning
days (PD 30-34) On PD 36, rats were injected with cocaine (10 mg/kg, IP) and
placed in photobeam activity chambers for 2 h. *Indicates significant difference
between cocaine-treated rats and rats treated with either saline or CP 55,940.
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CHAPTER NINE
DISCUSSION
In two experiments, the present thesis examined the effects of repeated
exposure to CP in early adolescent SD male and female rats using the
behavioral sensitization paradigm. In this paradigm, the behavioral response to a
drug is assessed after prior exposure to that drug. If the behavioral response is
augmented when re-exposed to the drug, then sensitization has occurred.
Behavioral sensitization has become an important tool in preclinical
investigations, as a sensitized response to a drug is indicative of its abuse
potential and is believed to be particularly associated with drug seeking behavior
(Robinson & Berridge, 2003). The first experiment examined whether repeated
CP exposure, over a range of doses, would differentially affect behavior after a
later challenge dose of CP. The second experiment assesed effects of repeated
CP exposure on later cocaine-induced behavioral sensitization and conditioned
activity. It was hypothesized that repeated CP would induce an augmented (i.e.,
sensitized) response to both CP (Experiment 1) and cocaine (Experiment 2) in
male and female rats. It was also predicted that female rats would have a
greater sensitized response, when compared to males, and that both CP and
cocaine would induce conditioned activity (Experiment 2).
In contrast to the predictions, repeated exposure to CP in Experiment 1
did not induce sensitization in adolescent rats at any dose or in either sex.
Female rats were, however, more active than male rats during the pretreatment
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phase. Similar to Experiment 1, pretreatment with CP did not enhance cocaineinduced activity or produce conditioned activity in adolescent rats. In
comparison, repeated exposure to cocaine did induce an augmented response to
both cocaine (behavioral sensitization) and saline (conditioned activity) challenge
in male and female adolescent rats.
The failure to find CP-induced behavioral sensitization was somewhat
surprising as a sensitized response to both synthetic cannabinoids and THC has
been observed in adult rats (Cadoni et al., 2001, 2008; Rubino et al., 2001;
Varvel, Martin & Lichtman, 2007). For example, 10 days of treatment with the
synthetic cannabinoid WIN (0.1 mg/kg) produced an augmented locomotor
response after a 48 hr abstinence period (Enayatfard et al., 2013). Adult rats
also show behavioral sensitization after treatment with THC; however, a
sensitized response is only observed when the dose of THC is increased each
day during the pretreatment phase (Cadoni et al., 2001, 2008; Rubino et al.,
2001). The use of an increasing dose regimen is believed to mimic recreational
cannabis users who are likely to increase their dose over time (Ellickson,
Martino, & Collins, 2004). Adolescent rats are often more sensitive to
psychoactive drugs than adult rats (For review, see Izenwasser, 2005), so it was
expected that they too would show a sensitized response. A possible
explanation is that cannabinoids may be different from other psychoactive
compounds, with adolescents showing less behavioral activation after exposure
(McKinney et al., 2008).
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Alternately, the inability to observe sensitization to CP may be a
consequence of our procedures. In behavioral sensitization studies the drug is
typically given once a day for a 1 to 10 day period (Caster et al., 2005;
Enayatfard et al., 2013; Kozanian, Gutierrez, Mohd-Yusof & Mc Dougall, 2012;
McDougall, Duke, Bolanos & Crawford, 1994; McDougall et al., 2007; Robinson
& Berridge, 1993; Vezina, 1996). In many of the investigations showing
cannabinoid sensitization, the drug was either given in an escalating dose or
multiple doses were given each day (Cadoni et al., 2001, 2008; Enayatfard et al.,
2013; Rubino et al., 2001). This pattern suggests that the neuronal modifications
necessary to induce sensitization after cannabis exposure requires a more
intense treatment than drugs such as cocaine and amphetamine, which produce
sensitization after a single exposure (Caster et al., 2007; McDougall et al., 2009).
Therefore, it is likely that cannabis sensitization in adolescents may be possible
with a more intense dosing paradigm (Cadoni et al., 2001, 2008; Enayatfard et
al., 2013; Mathews et al., 2011; Rubino et al., 2001). Importantly, these data
may suggest that enhanced drug sensitivity can only be seen in populations that
escalate their dose; whereas, consistent dose regimens used for medicinal
reasons (Häuser et al., 2018; Sulak, Saneto & Goldstein, 2017) may not have the
same detrimental impact (Kononoff et al., 2018; Melas et al., 2018).
It is also possible that the inability to find sensitization in adolescent rats is
specific to the cannabinoid chosen for this investigation and is not indicative of
other cannabinoids. CP is a potent agonist of the CB1 receptor system
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(Pertwee, 1997) and may not produce effects that are similar to other
cannabinoids which cause sensitization (Cadoni et al., 2001, 2008; Enayatfard et
al., 2013; Rubino et al., 2001). The cannabis plant contains a number of
cannabinoids that are not well understood and may contribute to the addictive
properties of cannabis use (Andre, Hausman & Guerriero, 2016). The synergistic
relationship that of cannabinoids may contribute to the rewarding effects
experienced by a user, and are not observed when a synthetic full CB1 agonist is
examined (McLaughlin, 2018; Russo & Guy, 2006). Thus, research focused on
THC alone or synthetic cannabinoids may not be sufficient to understand the full
behavioral response to cannabis. It may be necessary to compare how animals
respond to the effects of vaporizing the cannabis plant to gain a better
understanding of cannabinoid sensitivity (Baxter-Potter, Lugo, Fuchs, &
McLaughlin 2017; McLaughlin, 2018).
This study also examined cocaine-induced sensitization and found that
cocaine pre-exposure led to behavioral sensitization in adolescent rats. Cocaineinduced behavioral sensitization develops early in rats and can be observed in
rats at PD 19 (McDougall et al., 2007), and thus, sensitization was not
unexpected. However, previous research has demonstrated a number of agedependent effects in the sensitization to cocaine (McDougall et al., 1994, 1999,
2007; Zavala et al., 2000). For instance, preweanling rats show cocaine
sensitization at doses similar to adults; however, the sensitized response in
preweanling rats does not show persistence and is not apparent after 7 days

56

(Zavala et al., 2000). While sensitization in adult rats can be observed for
months after the last drug exposure (Leith & Kuczenski, 1982). Previous
research also indicates that the adolescent sensitized response is not the same
as an adult or preweanling rats (McDougall et al. 1994, 1999, 2007; Zavala et al.,
2000), as preweanling and adult rats show cocaine-induced sensitization after
only one drug exposure while adolescent rats do not. As predicted, this study
also found conditioned activity in rats that were pretreated with cocaine and
challenged with saline on the test day. This finding showed that early adolescent
rats respond in an adult-like fashion to the conditioning effects of cocaine.
Although this thesis found that pre-exposure to cocaine led to sensitization
after a cocaine challenge, there was no evidence that adolescent rats showed
cannabinoid-induced cross-sensitization to cocaine. Unlike CP, THC does
induce cross-sensitization to cocaine in older adolescent rats, but only after
increasing doses of cocaine (Dow-Edwards & Izenwasser, 2012). Similarly, an
escalating dose of WIN given to adolescent rats (PD 42) over an 11-day period
causes cross-sensitization to cocaine (10 mg/kg) 24 h later (Melas et al., 2018).
The present investigation showed that cross-sensitization to cocaine does not
occur after a five-day consistent-dose regimen of CP, suggesting that a more
intense drug exposure is necessary for cannabinoid sensitization to occur. Thus,
these data propose that changes in drug sensitivity may not occur in cannabis
users that do not increase their doses. For example, early high users that use a
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consistent high dose of cannabis and stable light users that use a consistent low
dose of cannabis (Ellickson et al., 2004).
The failure to find sensitization or cocaine cross-sensitization after
exposure to CP is inconsistent with the cannabis gateway theory of drug use.
The gateway theory postulates that cannabis use increases the likelihood of later
experimentation with illicit substances (Fergusson, Boden & Horwood, 2005;
Secades-Villa, Garcia-Rodiguez, Jin, Wang, & Blanco, 2015). A sensitized
response to CP or cocaine would support the hypothesis that adolescent
exposure to a cannabinoid causes an enhanced response when the individual is
later exposed to these drugs. Instead, we found that CP exposure did not lead to
an enhanced behavioral response to CP or cocaine suggesting that the gateway
theory does not apply with this combination or compounds. In addition the lack
of behavioral sensitization to CP suggests that moderate consistent treatment
with a cannabinoids does not activate in physiological processes that drive drug
seeking behavior. This finding suggests that other factors, such as environment,
mental health and economic status, may play a more vital role in an adolescent’s
motivation to continue to use cannabis or experiment with other illicit substances
(Fergusson et al., 2005; Secades-Villa et al., 2015).
In conclusion, little is known about the adolescent response to cannabis
exposure. Acquiring this information is important to fully understand the abuse
potential, addictive properties, and long term consequences of cannabinoidbased therapies. The present study examined the repeated exposure to the

58

synthetic cannabinoid agonist CP in adolescent male and female rats to assess if
it would alter drug responsivity. Our data indicated that repeated treatment with
CP in adolescent rats does not alter drug responsivity to a later drug challenge of
CP or cocaine. These data suggest that the use of a consistent dose CP by
adolescents does not alter drug sensitivity and is supportive of the medicinal use
of cannabinoids; however, additional research, testing other cannabinoids, is
wanted.
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